Avilar Therapeutics

Founded in 2006 and headquartered in Boston, US, Avilar Therapeutics is engaged in the development of advanced protein degradation therapies.57 mn.Avilar Therapeutics specializes in the development of protein degradation therapies, focusing on a novel class of degraders known as ATACs (ASGPR Targeting Chimeras). These products are designed to target extracellular and membrane-bound proteins, expanding the applications of protein degradation beyond traditional intracellular mechanisms. The ATACs utilize a natural endogenous process for protein degradation, aiming to address significant unmet medical needs associated with various serious diseases, given that nearly 40% of human proteins are located outside of cells.Avilar Therapeutics's revenue model centers on strategic partnerships and collaborations with larger pharmaceutical companies, allowing for shared development costs and access to broader markets. Transactions typically involve agreements for the licensing and commercialization of their proprietary ATACs, structured to include milestone payments tied to developmental progress and royalties based on product sales. The company’s flagship products, the ATACs, are positioned for impact in therapeutic markets, with potential pricing reflecting their innovative nature. The company is also looking to expand its reach into new markets, particularly targeting regions in Europe and Asia by 2025 to enhance their global footprint in the biotechnology sector.

1. Seed

   Feb 10, 2023

   Amount

   $55M

   Investors

   Locked

2. Seed

   Dec 14, 2020

   Amount

   $20M

   Investors

   Locked